Artivion, Inc.

Artivion, Inc. is a medical device company that manufactures, processes, and distributes medical devices and implantable human tissues globally. Its product portfolio includes On-X prosthetic aortic and mitral heart valves, On-X ascending aortic prosthesis, and various stent graft systems such as E-vita Open NEO, NEXUS ONE, and NEXUS DUO for aortic arch repair. The company also offers synthetic vascular grafts for open aortic and peripheral vascular surgeries, BioGlue surgical sealant, CryoValve SG pulmonary heart valve, and CryoPatch SG pulmonary cardiac patch. Additionally, Artivion provides vascular preservation services and utilizes SynerGraft decellularization technology. The company markets its products primarily to physicians through a direct sales team to hospitals and healthcare facilities.

Artivion, Inc. is listed on the New York Stock Exchange (NYSE) under the ticker symbol AORT. The company's financial reporting and stock trading are conducted in US Dollars (USD). Being listed on the NYSE, one of the world's largest stock exchanges, provides Artivion with access to a broad base of investors and liquidity. The use of USD as the reporting currency aligns with its headquarters in the United States and its primary operations in the country.

Artivion, Inc. operates in the Healthcare sector, specifically within the Medical Devices industry. As a medical device company, it focuses on developing and commercializing products used in cardiovascular and vascular surgeries. The company's offerings include prosthetic heart valves, stent grafts, surgical sealants, and implantable human tissues, all of which are critical in treating conditions related to the heart and blood vessels. The Medical Devices industry is highly regulated and requires significant investment in research and development, as well as compliance with standards set by health authorities such as the FDA.

Artivion, Inc. is headquartered in Kennesaw, Georgia, United States. The company was incorporated in 1984 and has since grown to serve global markets. Its products and preservation services are marketed primarily to physicians through a direct sales team to hospitals and healthcare facilities worldwide. The company's global reach is evident from its description stating that it manufactures, processes, and distributes medical devices and implantable human tissues globally. While the headquarters is in the US, the company's operations and customer base extend internationally, making it a key player in the global medical device market.

Artivion's product portfolio includes a wide range of medical devices for cardiovascular and vascular procedures. Key products include On-X prosthetic aortic and mitral heart valves, which are mechanical heart valves designed for durability and reduced need for anticoagulation. The company also offers stent graft systems such as E-vita Open NEO for hybrid aortic arch repair, NEXUS ONE and NEXUS DUO for endovascular aortic arch repair, and E-vita thoracic 3G for thoracic aortic aneurysms. Additionally, Artivion provides BioGlue surgical sealant used to seal tissue in vascular surgeries, CryoValve SG pulmonary heart valve and CryoPatch SG pulmonary cardiac patch, which are cryopreserved human tissues. The company also offers synthetic vascular grafts and utilizes SynerGraft decellularization technology to reduce immunogenicity.